Goldman Sachs Group Inc Ascendis Pharma A/S Call Options Transaction History

Goldman Sachs Group Inc

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $4.06 Million - $5.51 Million	35,900 Added 394.51%	45,000 $6.72 Million
Q2 2024 Aug 13, 2024	BUY	$121.07 - $153.67 $1.1 Million - $1.4 Million	9,100 New	9,100 $1.24 Million
Q1 2023 May 14, 2024	BUY	$104.9 - $126.78 $2.14 Million - $2.59 Million	20,400 Added 309.09%	27,000 $2.89 Million
Q1 2023 May 11, 2023	BUY	$104.9 - $126.78 $2.14 Million - $2.59 Million	20,400 Added 309.09%	27,000 $2.89 Million
Q4 2022 May 14, 2024	SELL	$99.42 - $131.97 $6.8 Million - $9.03 Million	-68,400 Reduced 91.2%	6,600 $806,000
Q4 2022 Feb 13, 2023	SELL	$99.42 - $131.97 $6.8 Million - $9.03 Million	-68,400 Reduced 91.2%	6,600 $806,000
Q3 2022 May 14, 2024	BUY	$84.03 - $110.23 $6.3 Million - $8.27 Million	75,000 New	75,000 $7.74 Million
Q3 2022 Nov 10, 2022	BUY	$84.03 - $110.23 $6.3 Million - $8.27 Million	75,000 New	75,000 $7.74 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.